Analysis of the effect of platinib (Pujihua) combined with other targeted drug treatment

Pralsetinib (Pralsetinib) is a highly selective RET kinase inhibitor, mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC), thyroid cancer and some other solid tumors. With the development of precision medicine, researchers are trying to combine platinib with other targeted drugs to enhance the anti-tumor effect, delay the occurrence of drug resistance, and cover more patient groups with abnormal signaling pathways.

Some clinical studies have tried to combine platinib with EGFR or ALK inhibitors for NSCLC patients with multiple driver gene mutations. The combination regimen shows that patients with RET fusion positivity and EGFR mutations can achieve a higher tumor response rate in the short term. (ORR) and longer progression-free survival (PFS), especially for patients whose tumor progression cannot be adequately controlled by single-agent therapy.

In recent years, research has also focused on the use of platinib in combination with immune checkpoint inhibitors or VEGF inhibitors. Preliminary data show that combination immunotherapy can enhance anti-tumor activity mediated by TT cells, but caution needs to be paid to potential immune-related side effects. Combination with VEGF inhibitors may inhibit tumor angiogenesis, improve drug distribution, and enhance overall efficacy, but cardiovascular and bleeding risks require careful monitoring.

Although combined medication shows certain advantages in efficacy, it may also increase adverse reactions, such as hypertension, abnormal liver function, hematological toxicity and gastrointestinal reactions. Clinically, an individualized plan should be formulated based on the patient's genetic profile and tolerance, and the efficacy and safety should be evaluated through regular blood routine, liver and kidney function, and imaging monitoring. Overall, platinib combined with other targeted drugs provides a new treatment option for patients with RET fusion-positive and complex genetic backgrounds, but more studies are still needed to verify the long-term benefits.

Reference link:https://www.drugs.com